Compare Invesco Preferred ETF (PGX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Preferred ETF vs Zimmer Biomet Holdings Inc — how do they compare? Invesco Preferred ETF trades at $10.04 (market cap $3.64B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.88B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.6× Invesco Preferred ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Preferred ETF for 94 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| PGX | ZBH | |
|---|---|---|
Market Cap | $3.64B | $16.88B |
Volume | 6,969,114 | 1,991,354 |
52-Week High | $11.61 | $103.98 |
52-Week Low | $9.97 | $79.58 |
Typical Hold Time | 94 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $23.95B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGX trades at $9.97, down 0.89% with a bearish technical signal from moving averages despite oversold RSI readings. The stock shows identical support and resistance at $10, indicating consolidation. Recent dividend payments of $0.06 were declared for July and September 2026, providing income appeal. Financial ratios including P/E, P/S, and ROE are unavailable in current data, limiting fundamental visibility.
The outlook remains cautious due to bearish technical momentum and lack of current financial metrics. Income investors may find dividend payments attractive, but absence of earnings data and weak price action suggest near-term pressure. Key risks include undefined profitability and competitive challenges in the preferred ETF space highlighted by recent media coverage.
Zimmer Biomet (ZBH) trades at $88.91, down 0.86% on the day, with a bearish technical signal from moving averages. The company reported revenue of $8.23B in 2025, with net income of $705.1M, and has beaten EPS estimates for the last three quarters. Recent news highlights a quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The outlook is mixed: strong fundamentals and consistent earnings beats support growth, but technical indicators and rising debt-to-asset ratios pose risks. Analyst consensus suggests a 16% upside to the $103.11 price target, though nearly half of analysts recommend Hold. Key risks include competitive pressures and execution of the company's strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
